What Detantol Treats: Main Uses and Benefits

Detantol is commonly used to help with symptoms related to systemic imbalance, such as in hypertension, and is relevant for easing symptoms linked to organ-specific functional stress, such as in benign prostatic hyperplasia (BPH). It is also applicable in addressing symptoms associated with elevated intraocular pressure in conditions like glaucoma and ocular hypertension. The medication is applied across therapeutic domains involving heightened responses and is a component of symptomatic management for these conditions. This supportive role contributes to easing the overall symptom load, which is relevant for systems marked by temporary physiological imbalance. The topical form, in particular, may assist with maintaining a sense of stability when symptoms are more noticeable in ocular health.

“The application is generally considered relevant when supportive symptom management is appropriate across pressure-related conditions.”

Quick Fact: Support for Pressure and Flow Symptoms

Detantol assists with maintaining functional stability when symptoms interfere with routine activities, and contributes to improved comfort during periods of heightened pressure or flow symptoms.

Eligibility Map: Who Can and Cannot Use Detantol — Official Regulatory Information

Eligibility Scope

Population Status	Regulatory Rule
Allowed	Adults (typically 18+); Older Adults up to age 80; Patients with moderately impaired renal function.
Not Recommended	Patients with severe hepatic impairment; Individuals with severe obesity (BMI > 30 kg/m²); Patients with severe renal impairment (requires caution).
Contraindicated	Patients with known hypersensitivity to Bunazosin or other quinazoline derivatives.

Condition-Specific Exclusions

Detantol is officially excluded for populations with certain severe clinical histories for the systemic form. This includes women who are pregnant or lactating (breastfeeding). Use is also restricted for patients with a history of Severe Heart Failure (LVEF < 40%), Stroke, Myocardial Infarction, or Severe Arrhythmia.

Age-Related Status

Use is not established in the pediatric population (children and adolescents) due to insufficient data. The medicine is intended only for the adult and older adult populations.

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use Detantol by establishing absolute prohibitions based on reproductive status and specific, severe cardiovascular histories. Eligibility is strictly confined to adult populations where the risk profile concerning drug-class hypersensitivity and organ function (renal/hepatic) is deemed acceptable or manageable under label constraints.

The regulatory profile for Detantol (Bunazosin), a selective alpha-1 antagonist, details two primary categories of interaction: pharmacodynamic effects and altered pharmacokinetic clearance. Co-administration with other antihypertensive agents and Phosphodiesterase Type 5 (PDE5) Inhibitors (such as sildenafil or tadalafil) is formally documented to cause additive blood pressure lowering effects. This is recognized in official labeling as a clinically significant interaction due to the risk of symptomatic hypotension.

The pharmacokinetic profile indicates that co-administration with strong CYP3A Inhibitors may increase the systemic exposure and plasma concentrations of Detantol by reducing its clearance. The official drug information also notes that interactions may occur with certain over-the-counter medicines, dietary supplements, and herbal products, which may enhance or diminish the effects of the medicine.

Official Interaction Outcomes

Interaction Domain	Interacting Substances/Conditions	Regulatory Outcome
Pharmacodynamic Potentiation	Other Antihypertensive Agents, PDE5 Inhibitors	Additive blood pressure lowering; risk of symptomatic hypotension
Pharmacokinetic Reduction	Strong CYP3A Inhibitors, Select Calcium Channel Blockers	Increased systemic exposure; reduced drug clearance
Population-Specific Constraint	Impaired Hepatic or Renal Function	Significant increase in systemic exposure (AUC and Cmax)

There are no combinations formally classified as absolute contraindications or mandatory timing separation rules documented in the official prescribing information. The interaction structure strictly describes the mandatory constraints and outcomes as formally stated in regulatory labeling.

How Detantol Works

Detantol (Bunazosin) operates through antagonism of the Alpha-1 (mathbfalpha1) adrenergic receptors found on the surface of smooth muscle cells. This interaction prevents endogenous catecholamines, such as norepinephrine, from binding and initiating the cell's response. The blockade of the alpha1 receptor pathway functionally suppresses the activation of the Intracellular Calcium (mathbfCa^2+) mobilization signal, which is required for the smooth muscle fibers to contract.

This molecular event translates into two distinct physiological consequences depending on tissue location. In the systemic circulation, the relaxation of smooth muscle in resistance vessels results in peripheral vasodilation and a reduction in the overall Systemic Vascular Resistance (SVR). In the eye, the same mechanism relaxes the ciliary muscle, structurally enhancing fluid egress via the non-conventional uveoscleral pathway, thereby modulating the organ's fluid pressure dynamics.

This widespread alpha1 antagonism mechanistically constrains the body’s ability to execute compensatory vasoconstriction. For topical application, the mechanism exhibits limited action on the alpha1 receptors of the iris dilator muscle.

Administration Scope

Detantol (Bunazosin) is administered via two distinct routes: Oral (as tablets for systemic use) and Topical (as an ophthalmic solution for localized ocular use). The oral regimen is characterized by a titration schedule, starting at 3 mg once daily. Dosing allows for gradual, step-wise increases up to a maximum daily dose of 9 mg, with adjustments made at specified intervals, such as every two weeks. The topical ophthalmic solution is administered at a fixed frequency of three times a day (TID), applying a single drop to the affected eye.

---

Special Administration Constraints

For proper systemic use, the tablets must be swallowed whole and not crushed or chewed to preserve the intended drug release profile. If a dose is missed, it should be taken as soon as possible, but skipped if it is close to the next scheduled time (e.g., less than half a day away) to maintain a regular schedule. Procedural constraints for the topical form include allowing at least a 10-minute interval if other eye drops are administered. The controlled-release form is utilized in cases of moderate renal impairment following the standard titration schedule without initial dose reduction.

---

Connection to the Overall Use Protocol

These instructions define the standardized approach to using the medicine. The protocol is structured by its dual-route approach that requires distinct frequencies and procedural steps based on the dosage form. The rules mandate a gradual titration sequence for the systemic dose, while requiring the oral tablet be administered without modification. For ocular use, the instructions establish a fixed TID schedule and define specific procedural conditions for application.

Detantol: Recent Clinical Evidence

---

Summary of Primary Research Focus

Initial research focused on the drug's selective inhibition of the enzyme COX-2. Early trials and subsequent research have evaluated whether it affects joint function and stiffness in conditions such as osteoarthritis and rheumatoid arthritis. Studies have examined whether the drug is associated with a reduction in pain and stiffness, with many focusing on its potential role in modulating inflammatory pathways.

---

Clinical Study Findings

Pain and Inflammation

Studies have primarily focused on the drug's effects on acute and chronic pain, comparing outcomes across various patient groups.

• Initial Focus: Early-stage investigation focused on the drug's relationship with the selective inhibition of COX-2 and subsequent changes in inflammation levels.
• Pharmacokinetics: Studies investigated whether the combination affects absorption and bioavailability.
• Patient Tolerability: The drug's side effect profile and tolerability have been subjects of monitoring in clinical trials.

Comparison to Other Treatments

Some research has compared its effects to standard NSAIDs (Non-Steroidal Anti-inflammatory Drugs) and placebo groups.

• Osteoarthritis (OA): Several large trials evaluated its use in OA. The primary endpoints in these trials were typically changes in self-reported pain scores (e.g., VAS or WOMAC scores) and physical function assessments. Findings from different trials have been varied regarding the magnitude and duration of effect when compared to placebo.
• Rheumatoid Arthritis (RA): Research examined its potential use in managing RA symptoms. Studies specifically evaluated whether the drug affected joint tenderness and swelling counts.

Safety and Side Effects

Clinical research has extensively monitored potential adverse events, particularly focusing on cardiovascular and gastrointestinal risks.

• GI Profile: Research explored outcomes related to upper GI complications (ulcers, bleeds) in comparison to non-selective NSAIDs.
• CV Risk: Dedicated trials have examined whether there is any relationship between the drug's use and cardiovascular events such as myocardial infarction or stroke.
• Interactions: Research has also explored the drug's interaction profile with other common co-administered medications.

Key Studies & References

1. NICE Guideline NG212: Osteoarthritis: care and management in adults.

Common questions about Detantol (FAQ)

Q: Is Detantol the same kind of medicine as [similar drug name]?

Detantol’s active ingredient, Bunazosin, is officially classified as a selective Alpha-1 adrenergic receptor antagonist, commonly known as an alpha1-blocker. Official regulatory documents focus on describing the properties and effects of the active ingredient. The labeling does not include direct comparisons to other specific brand names or competitor drugs.

Q: What happens if I forget to use Detantol one time?

Official administration instructions provide a procedure for a missed dose. The procedure outlined in the label is that the dose may be taken as soon as it is remembered, provided it is not close to the next scheduled time. If it is near the next dose, the procedure outlined in the label is to skip the forgotten dose to help maintain a regular schedule.

Q: Are there any foods or drinks I should know about when using Detantol?

The official regulatory profile notes potential interactions with certain dietary supplements, herbal products, and over-the-counter medicines. These products may alter the intended effects of Detantol. There are no specific restrictions for food or non-alcoholic drinks documented in the formal interaction warnings.

Q: Can I use alcohol while I am taking Detantol?

Official documents describe the potential for additive blood pressure lowering effects when Detantol is combined with other agents that reduce blood pressure. Since alcohol can also affect blood pressure, this combination may increase the risk of symptomatic hypotension, which includes symptoms like dizziness or lightheadedness.

Q: Does Detantol cause weight gain or weight loss?

Regulatory documents classify the known side effects by their frequency in clinical use. Weight change (either gain or loss) is not listed among the Very Common or Common adverse reactions documented in the official safety profile for Detantol.

Q: What evidence exists about Detantol's use in pregnant individuals?

Official regulatory documents define the use of Detantol as restricted in women who are pregnant. This restriction is based on the lack of established safety and clinical data regarding the use of the drug in this specific population.

Q: Are there any known risks of taking Detantol while breastfeeding?

According to official documents, the use of Detantol is restricted in women who are lactating (breastfeeding). This restriction is in place because of the lack of established safety and clinical data for the drug's use in this population.

Q: What are the most common things people say they feel when starting Detantol?

Official safety statements note that the highest reported risk for specific symptoms occurs upon the initiation of therapy or following a rapid increase in dosage. These effects include fainting (Syncope) and marked lightheadedness/dizziness (Postural Hypotension), which are linked to the drug’s action on blood pressure.

Q: Can I take Detantol with my vitamins or supplements?

The official regulatory profile notes that interactions may occur with certain dietary supplements and herbal products. These substances may alter or affect the intended benefits and safety profile of the medicine.

Q: How long does it typically take to notice the intended effects of Detantol?

The official prescribing instructions for the oral medicine describe a gradual titration schedule, where the dose is increased in specified increments over regular intervals. This gradual schedule is the structured process through which the intended effects are established and monitored.

Q: Is it okay to use Detantol if I have high blood pressure?

The drug’s official purpose is directly linked to its function as a systemic antihypertensive medication. The drug's role, as described in official documents, is to reduce systemic blood pressure by promoting vasodilation.

Q: What should I know about using Detantol before driving or operating machinery?

Official safety labeling lists effects such as dizziness and drowsiness among the common adverse reactions. The presence of these effects means that caution is typically required when engaging in activities such as driving or operating machinery.

Q: How long does the effect of one dose of Detantol usually last?

The official instructions define the administration frequency intended to maintain the drug’s effect. For the oral tablet, administration is defined as once daily, and for the ophthalmic solution, the defined frequency is three times a day (TID).

Q: How does the official labeling describe the expected outcome of using Detantol?

The intended outcome of using the medicine is linked to its ability to promote peripheral vasodilation, which means widening the blood vessels. This action reduces the resistance in the circulatory system, resulting in a reduction in overall Systemic Vascular Resistance (SVR) and blood pressure.

Q: Does Detantol require a special diet or monitoring while being used?

Official documentation notes that specific consideration is required for individuals with impaired hepatic or renal (liver or kidney) function because of the potential for increased systemic exposure. However, no official regulatory statement mandates the adoption of a specific special diet while using the medicine.

Q: What is the difference between Detantol and a generic version of the medicine?

Detantol is the brand name for the medicine, and the sole active ingredient is Bunazosin hydrochloride. Official regulatory documents and rules focus on the established pharmacological properties and safety of the active ingredient regardless of whether the product is brand-name or generic.

Q: Is Detantol meant to be used long-term or short-term?

The official administration schedule describes a titration schedule for the systemic dose, where adjustments are made over several weeks, which is suggestive of ongoing use. The duration of treatment is determined in consultation with a health professional.

Q: Is Detantol available over the counter?

Based on official records, Detantol is classified as a prescription-only medication. It cannot be obtained without a prescription from a licensed health professional.

Q: Is Detantol related to or derived from any natural substances?

Detantol’s active ingredient, Bunazosin, is officially defined as a synthetic compound. It is chemically manufactured and derived from the quinazoline chemical structure.

Storage & Disposal Map: How to Store and Dispose of Detantol — Official Regulatory Information

Storage & Disposal Scope

• Labeled storage temperature requirements: Must be kept away from heat.
• Light/moisture protection requirements: Must be kept away from light, direct sunlight, and moisture.
• Stability after opening/reconstitution (if applicable): No specific 'in-use' stability period was found in the available regulatory documents; stability is maintained by avoiding light, heat, and moisture.
• Handling requirements: Protection from light, heat, and moisture is required. The ophthalmic solution includes a handling instruction to not give it to others.
• Packaging-related storage rules (if applicable): Not documented in available regulatory sheets.
• Disposal instructions (as documented in government sources): Any leftover or unused medicine must be disposed of appropriately and not kept. For the ophthalmic solution, if the disposal method is unknown, a pharmacy or medical institution must be consulted.
• Environmental or controlled-waste disposal requirements (if applicable): Disposal must be appropriate for leftover product.
• Child-protection storage requirements (if stated): Must be kept out of the reach of children.

---

Storage/Disposal Classifications (High-Level)

Classification	Requirement
Storage condition type	Protect from light, heat, and moisture.
In-use stability classification	Stability is maintained by adhering to the required protection conditions.
Regulatory basis	PMDA / MHLW (Japan) official Drug Information Sheets.
Storage-context constraints	Must be kept out of the reach of children; must avoid direct sunlight, heat, and moisture.

---

Resulting Storage & Disposal Structure

The official regulatory documents for Detantol tablets and ophthalmic solution define storage by requiring protection from environmental conditions, specifically mandating that the medicine be kept away from light, heat, and moisture to ensure product stability. Mandatory safety requires the medicine to be stored out of the reach of children. Disposal rules dictate that all leftover products must be discarded appropriately and not retained, and the ophthalmic solution must not be given to others.